1Pellegata NS,Sessa F,Renault B,et al. K-ras and P53 gene mutations in pancreatic cancer:ductal and nonductal tumors progress through different genetic lesions. Cancer Res, 1994, 54: 1556 ～1560.
2Yanagisawa A,Ohtake K,Ohashi ZK,et al. Frequent K-ras oncogene activation in mucous cell hyperplasia of pancreas suffering from chronic inflammation. Cancer Res, 1993,53 (5): 953～ 956.
4Kleff J,Ishiwata T,Friess H,et al. The helix-loop-helix protein ld2 is overexpressed in human pancreatic cancer. Cancer Res,1998,158(17) : 3769～3772.
5Sato YT, Nio YN, Song MM, et al.P53 protein expression as prognostic factor is human pancreatic cancer. Anticancer Res,1997,17:2779.
6CaldasC, Hahm SA, Decosta LT, et al. Frequent somatic mutations malignant and homozygous deletions of the P16 (MTS1)gene in pancreatic adenocarcinoma. Nat Genet, 1994,8: 27.
7Naumannn M,Savitskaia M,Eilert C,et al. Frequent codeletion of P16/MTS1 and P15/MTS2 and genetic alterations in P16/MTS1 in pancreatic tumors. Gastroenterology, 1996,110:1215.
